Abstract: A method of treating gum disease while healing the wound in the periodontium using a soft tissue diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate the periodontium to regenerate and heal its wound when used with substrates, the method comprising: placing the tip of the laser inside the sulcus; penetrating the entire sulcus by moving the laser light circumferentially around the tooth vertically and horizontally throughout the sulcus with intermittent stops to control tissue temperature and placing substrates in the sulcus prior to blood clot formation; followed by RF treatment of the sulcus by placing the RF headpiece tips perpendicular to the sulcus to receive RF current which further penetrates the wound site.

Abstract: An dual oral composition is provided having a first peroxide-containing component and a second bicarbonate-containing component having exceptional anti-plaque and antibacterial action with re-mineralization properties.

Abstract: The invention relates to non-aqueous dentrfrice compositions comprising a surfactant system. The surfactant system consists of a combination of surfactants i.e. a betaine and a taurate surfactant; or a betaine and an alkyl sulphate surfactant; or a betaine, a taurate and an alkyl sulphate surfactant.

Abstract: Composition for use in the remineralization of teeth, which comprises a fluoride-containing component and a calcium-containing component, wherein the calcium-containing component contains a nanoparticulate calcium salt and the composition is designed for the successive application of the fluoride-containing component and the calcium-containing component to the tooth surface, wherein the fluoride-containing component is applied to the tooth before the calcium-containing component.

Abstract: Oral care compositions with an anticaries or anticavity effect. Oral care compositions that are have an extract from a species in the Humulus family and an anticaries drug, such as a fluoride ion source. Oral care compositions have fluoride and hops beta acid, such as from an extract from Humulus lupulus. Oral care compositions have a fluoride ion source and a hops beta acid derived from an extract of Humulus lupulus.

Abstract: Oral care compositions that have hops beta acid, such as from an extract from a species in the Humulus family, and a metal ion source, such as a tin ion source and/or a zinc ion source. Oral care compositions that have a tin ion source and/or a zinc ion source and one or more hops beta acids, such as from an extract from Humulus lupulus. Oral care compositions have a tin ion source and/or a zinc ion source and a beta acid derived from an extract of Humulus lupulus.

Abstract: A medical device or solution for treating dental discomfort by at least partially occluding dental tubules is disclosed. The medical device or solution contains a polysaccharide or other biocompatible polymer with an antimicrobial metal, antimicrobial metal compound, or antimicrobial metal ion bound to a biopolymer. The medical device or solution further comprises at least one soluble antimicrobial. The soluble antimicrobial may be a water soluble metal iodide, water soluble metal fluoride, or a water soluble metal chloride encompassed with the nanogel. The medical device may be a solution of a chitosan with a nanoparticle of silver fluoride on the chitosan and at least one of a sodium fluoride or silver fluoride. The solution may be water based solution. Methods of applying the medical device or solution are also disclosed.

Abstract: A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.

Abstract: The present invention provides for devices and methods of treating wounds, including general wounds, gum disease and gingival tissues post scaling/root planning, using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm). Further disclosed are devices and methods capable of stimulating tissue regeneration at the site of a wound.

Abstract: Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of gum disease or halitosis comprising contacting the oral cavity with the oral care compositions disclosed herein, as well as methods of making the oral care compositions disclose herein.

Abstract: The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

Abstract: A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.

Abstract: A stabilised hypochlorous solution is disclosed. The solution includes hypochlorous acid (HOCl), hypochlorite (ClO—), and chlorine (Cl—) that combine to provide a total chlorine concentration. The total chlorine concentration is at or below 300 ppm, the hypochlorous acid, measured by UV spectroscopy at 230 nm, is the predominant species, the hypochlorite, measured by UV spectroscopy at 290 nm, is present at significantly lower levels than that of the hypochlorous acid, such that a ratio of hypochlorous acid to hypochlorite is greater than 7.5:1. The solution has a pH of between about 7 and 4 and a shelf life of at least 12 months, at 22° C., such that the amount of hypochlorous present remains at above 80% of its starting concentration, and the pH remains above 4.

Abstract: This application provides, among other things, novel aqueous monophasic compositions useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect against erosion and staining, by addition of a stabilizing amount of a polyamine, e.g. lysine, and methods for making and using the same.

Abstract: Dental compositions that comprise algae are disclosed. Methods of use of the dental compositions, including methods of reducing plaque on at least one tooth of an animal using the dental compositions, are also disclosed.

Abstract: The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

Abstract: Disclosed herein are aqueous compositions comprising fructose and methods of production thereof. A method for producing an aqueous composition comprising fructose can comprise, for example, conducting an enzymatic reaction by contacting water, sucrose, and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan having at least 30% alpha-1,3-linkages. A soluble fraction produced by such a reaction comprises at least about 55% fructose on a dry weight basis, and can be separated from insoluble poly alpha-1,3-glucan product(s), thereby providing an aqueous composition comprising fructose.

Abstract: Described herein are single-phase compositions and methods for its pharmaceutical and cosmetic use, comprising (i) a combination of N-acyl sarcosinate, (ii) an oxidative compound, and (iii) a buffering system in amounts and embodiments effective to protect the oxidative compounds from degradation prior to use and upon use and to enhance the efficacy of the composition in removing polymicrobial biofilms, reducing the re-growth of polymicrobial biofilms that leads to plaque formation, greater availability of chlorite ion for antimicrobial and cosmetic purposes, and effective oxidation of salivary biomolecules. When these single-phase compositions are comprised of a source of fluoride ion, they also achieve enhanced enamel fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization of teeth when compared to US Pharmacopoeia Reference Dentifrice, prior known toothpastes comprising stabilized chlorine dioxide and comparable commercial dentifrices.

Abstract: Oral care compositions comprising stannous ion source, neutral amino acid, and polyphosphate are provided for improved efficacy to help inhibit biofilm formation or help disrupt biofilm.

Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.